A federal watchdog found that vertically integrated pharmacy benefit managers dominate Medicare Part D plans, leading to higher out-of-pocket drug costs for enrollees. Read More »
Ryan Long of Paragon Health Institute said federal drug pricing programs like 340B often benefit wealthier hospitals over poorer ones. Read More »
We Work For Health Maryland called for reform of the federal 340B contract pharmacy program after new data showed high market concentration among major PBMs and chains. Read More »
Virginia Society of Rheumatology President Harry Gewanter said the 340B Drug Pricing Program no longer prioritizes patient needs but instead benefits large hospital systems financially. Read More »
Allvanza CEO Rosa Mendoza said that insufficient oversight has allowed the federal 340B drug pricing program to expand far beyond its original intent. Read More »
Public Policy Solutions has raised concerns about hospitals' use of the federal 340B drug pricing program. Read More »
PhRMA has raised concerns about private equity-backed health care entities using nonprofit status to access 340B revenues. Read More »
Katy Talento questioned why Medicare relies on pharmacy benefit managers instead of negotiating directly with pharmaceutical companies. Read More »
Sally Pipes of Pacific Research Institute said new federal proposals could bring needed transparency and accountability to the expanding 340B Drug Pricing Program. Read More »
Jackson Hammond of Paragon Health Institute called for reforms to end spread-based profit mechanisms in the federal 340B drug discount program. Read More »
Steve Forbes criticized the current state of the 340B drug discount program in a recent statement. Read More »
Kevin Roche said that hospitals have turned the federal 340B drug pricing program into a profit source rather than using it solely for poor patients as intended. Read More »
Former Governor Bobby Jindal said recent pharmacy benefit manager (PBM) reforms are an important first step toward greater transparency in drug pricing. Read More »
The American Legislative Exchange Council said on March 9 that the federal 340B Drug Pricing Program increases costs for taxpayers and patients while failing many underserved communities. Read More »
PhRMA released an analysis showing 340B hospitals buy drugs at discounts but apply high markups when billing insurers and patients. Read More »
Peter Mihalick of the American Medical Informatics Association said that the federal 340B Drug Pricing Program incentivizes nonprofit hospitals to prioritize profits over patient savings. Read More »
U.S. Representative Gabe Evans said pharmacy benefit managers have contributed to rising prescription drug costs and highlighted recent congressional action aimed at reforming their practices. Read More »
Dae Y. Lee called attention to a proposed Department of Labor rule that would require pharmacy benefit managers to reveal details about their revenue practices. He encouraged stakeholders to submit public comments before the March 31 deadline. State audits and legal actions have highlighted ongoing concerns over spread pricing and retroactive fees. Read More »
Anthony DiGiorgio from UCSF highlights concerns regarding the financial impact of the 340B drug discount program on taxpayers and employer plans. Read More »
The rapid expansion of the 340B Drug Pricing Program has sparked concerns over its effectiveness in improving access or reducing costs. Read More »
Alerts Sign-up
